JohannesCzerninMD

Professor, Molecular & Medical Pharmacology, UCLA School of Medicine Chief of the Ahmanson Translational Imaging Division at UCLA

Join to view full profile

Dr. Czernin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Czernin's full profile

Already have an account?

Office
200 Medical Plz
Ste 36553
Los Angeles, CA 90095
Phone+1 310-794-1005

Fax+1 310-267-0227
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Nuclear Medicine, 1994 - 1995
University of Vienna Faculty of MedicineClass of 1983

Certifications & Licensure

CA State Medical License 1996 - 2024
American Board of Nuclear Medicine Nuclear Medicine

Awards, Honors, & Recognition

Los Angeles Magazine Top Doctors 2018

Clinical Trials

PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma Start of enrollment: 2006 Jan 01
Completed
Not Applicable
Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants Start of enrollment: 2004 May 04
Terminated
Not Applicable
Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy Start of enrollment: 2004 Dec 01
Completed
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets Start of enrollment: 2009 Jan 01
Unknown status
Phase 3
Roles: Principal Investigator, Contact
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma Start of enrollment: 2012 Aug 22
Completed
Not Applicable
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer Start of enrollment: 2018 Apr 02
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Inventing His Own Career Path: Freek Beekman Talks with Johannes Czernin and Christine Mona About Success in Academia and Industry.
Freek Beekman, Christine Mona, Johannes Czernin> ;Journal of Nuclear Medicine. 2024 Apr 4
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
John Shen, Ankush Sachdeva, Tahmineh Romero, John Nikitas, Matthew Rettig, Robert Reiter, Alan Lee, Michael L Steinberg, Luca F Valle, Jeremie Calais, Johannes Czernin...> ;European Urology. 2024 Mar 16
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resist...
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, Jeremie Calais, Johannes Czernin, Harun Ilhan, Fred Saad, Alexander Kretschmer, Turkay Hekimsoy, Sabine D Brook...> ;European Urology. 2024 Mar 14
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospe...
Armstrong, W., Booker, K., Grogan, T., Elashoff, D., Lam, E., Clark, K., Fendler, W., Kishan, A., Steinberg, M., Hope, T., Nickols, N., Czernin, J., Calais, J.> ;European Urology. 2024 Jan 29
Differences and Common Ground inLu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
Andrea Farolfi, Wesley R Armstrong, Loic Djaileb, Andrei Gafita, Masatoshi Hotta, Martin Allen-Auerbach, Lena M Unterrainer, Wolfgang P Fendler, Matthew Rettig, Matthi...> ;Journal of Nuclear Medicine. 2024 Mar 1
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer.
Pienta, K., Moul, J., Shore, N., Czernin, J., King, M., Freedland, S.> ;Prostate Cancer and Prostatic Diseases. 2024 Jan 17
[Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor.
Unterrainer, L., Memarzadeh, S., Moatamed, N., Benz, M., Czernin, J., Calais, J.> ;Journal of Nuclear Medicine. 2024 Jan 11
Expanding the Mission and Influence of SNMMI: A Conversation Between Johannes Czernin and Virginia Pappas About Her Career in SNMMI Leadership.
Pappas, V., Czernin, J.> ;Journal of Nuclear Medicine. 2024 Jan 2
2 citations
PresurgicalGa-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
Loïc Djaïleb, Wesley R Armstrong, Daniel Thompson, Andrei Gafita, Andrea Farolfi, Abhejit Rajagopal, Tristan R Grogan, Kathleen Nguyen, Matthias R Benz, Masatoshi Hott...> ;European Urology. 2023 Dec 1
Characterizing Normal Variant [Ga]Ga-FAPI-46 Uptake in the Epididymis.
Peter George Maliha, Masatoshi Hotta, Johannes Czernin, Jeremie Calais> ;Journal of Nuclear Medicine. 2024 Jan 2
Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory ser...
Ida Sonni, Lena M Unterrainer, Rejah M Alano, Stephanie Lira, John Shen, Alexandra Drakaki, Tristan Grogan, Matthew B Rettig, Johannes Czernin, Jeremie Calais, Andrei ...> ;EJNMMI Research. 2023 Oct 30
Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo.
Kalevi Kairemo, Johannes Czernin> ;Journal of Nuclear Medicine. 2023 Nov 1
Tandem Isotope Therapy withAc- andLu-PSMA-617 in a Murine Model of Prostate Cancer.
Catherine Meyer, Andreea Stuparu, Katharina Lueckerath, Jeremie Calais, Johannes Czernin, Roger Slavik, Magnus Dahlbom> ;Journal of Nuclear Medicine. 2023 Nov 1
Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz.
Patricia A Ganz, Johannes Czernin> ;Journal of Nuclear Medicine. 2023 Oct 1
A Tribute to OurAssociate Editors.
Johannes Czernin> ;Journal of Nuclear Medicine. 2023 Oct 1
1 citations
Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated withLu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
Vishnu Murthy, Pan Thin, Kathleen Nguyen, Tristan Grogan, John Shen, Alexandra Drakaki, Matthew Rettig, Johannes Czernin, Jeremie Calais, Andrei Gafita> ;Journal of Nuclear Medicine. 2023 Nov 1
2 citations
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.
Neal D Shore, Judd W Moul, Kenneth J Pienta, Johannes Czernin, Martin T King, Stephen J Freedland> ;Prostate Cancer and Prostatic Diseases. 2023 Sep 7
2 citations
Application of next-generation imaging in biochemically recurrent prostate cancer.
Judd W Moul, Neal D Shore, Kenneth J Pienta, Johannes Czernin, Martin T King, Stephen J Freedland> ;Prostate Cancer and Prostatic Diseases. 2023 Sep 7
3 citations
Toward Integrated Independence: Johannes Czernin Discusses the Future of Theranostics with Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber.
Ebrahim S Delpassand, Eric M Rohren, Wolfgang A Weber, Johannes Czernin> ;Journal of Nuclear Medicine. 2023 Sep 1
2 citations
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States.
Johannes Czernin, Jeremie Calais> ;Journal of Nuclear Medicine. 2023 Sep 1
Editors' Choice Awards for 2022.
Johannes Czernin> ;Journal of Nuclear Medicine. 2023 Jul 1
Leading the European Society of Cardiology: A Conversation Between Franz Weidinger, Frank Bengel, and Johannes Czernin.
Franz Weidinger, Frank Bengel, Johannes Czernin> ;Journal of Nuclear Medicine. 2023 Jul 1
PSMA-Negative Lesion Progression UnderLu-PSMA Radioligand Therapy.
Vishnu Murthy, Martin Allen-Auerbach, Richard Lam, Dawn Owen, Johannes Czernin, Jeremie Calais> ;Journal of Nuclear Medicine. 2023 Sep 1
2 citations
[Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis.
Lena M Unterrainer, Anthony E Sisk Jr, Johannes Czernin, Brian M Shuch, Jeremie Calais, Masatoshi Hotta> ;Journal of Nuclear Medicine. 2023 Oct 1
Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [Ga]Ga-FAPI-46 PET-Positive and [F]FDG PET-Negative.
Peter George Maliha, Abie H Mendelsohn, Johannes Czernin, Taylor Howard, Jeremie Calais, Masatoshi Hotta> ;Journal of Nuclear Medicine. 2023 Nov 1
Join now to see all

Press Mentions

UCLA Researchers Receive Grant from Prostate Cancer FoundationDecember 14th, 2022
UCLA Health Earns Comprehensive Center of Excellence Designation for Radiopharmaceutical Therapy as Work Continues on New FacilityJune 29th, 2022
Breaking the Boundaries Between Radiology and Oncology: GU Oncology Profiles Thomas a. Hope, MDApril 28th, 2022
Join now to see all

Other Languages

German